VANCOUVER, Feb. 13 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in advancing novel, targeted therapeutic proteins, today announced that data
from the completed Phase 1 clinical study testing PRX302 in patients with
locally recurrent prostate cancer following radiation failure will be
presented at the American Society of Clinical Oncology ("ASCO") Genitourinary
Cancer Symposium in San Francisco, California.